MaxCyte, Inc.® VLX and STX Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing
1/29/2013 9:45:31 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs. The initial application of MaxCyte STX and VLX systems will be in fulfillment of a Department of Defense contract for the process development and manufacturing scale-up of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses in support of the ongoing preclinical evaluation of the efficacy, potency, and safety of these Filovirus vaccine candidates.
comments powered by